This Billionaire's Fund Returned 30% This Year; Here Are Some of His Top Stock Picks
Michael Hintze is the founder of multi-strategy asset management firm CQS Cayman. In 2016, Hintze's CQS Directional Opportunities fund posted a stunning 30% return.
Ariad Pharmaceuticals Inc (ARIA)
This company is not actively trading or the ticker does belong to another company in our database now.
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% | |
| 2. | Ironwood Investment Management Warren Isabelle | 0 | $0 | 0% | |
| 3. | Rhenman & Partners Asset Management Henrik Rhenman | 0 | $0 | 0% | |
| 4. | Paloma Partners Donald Sussman | 0 | $0 | 0% | |
| 5. | Platinum Asset Management Kerr Neilson | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.41 | 26,990 | $199,995.90 | 88,089 | 2016-05-12 | Filing | |
| $4.91 | 61,099 | $299,996.09 | 61,099 | 2016-02-01 | Filing | |
| $6.90 | 12,500 | $86,280.00 | 1,864,286 | 2015-02-12 | Filing | |
| $6.77 | 12,500 | $84,568.75 | 1,851,786 | 2015-02-11 | Filing | |
| $6.18 | 12,500 | $77,250.00 | 1,839,286 | 2015-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.78 | 32,000 | $760,960.00 | 129,404 | 2017-01-09 | Filing | |
| $9.56 | 19,638 | $187,739.28 | 197,884 | 2016-10-24 | Filing | |
| $13.46 | 47,384 | $637,812.33 | 129,404 | 2016-10-03 | Filing | |
| $13.98 | 8,750 | $122,311.00 | 217,522 | 2016-09-28 | Filing | |
| $13.43 | 20,000 | $268,536.00 | 208,772 | 2016-09-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
Hedge Funds Are Betting On Ariad Pharmaceuticals, Inc. (ARIA)
You probably know from experience that there is not as much information on small-cap companies as there is on large companies.
Five Stocks on the Move in the Wake of Trump's Election Win
Amid the calm backdrop, shares of five stocks, Ariad Pharmaceuticals, Inc.
Tamarack Capital Management's Ariad Pharmaceuticals, Inc. (ARIA) Holding Carries It To Strong Q3 Gains
Our data culled from the 659 funds in our database which filed 13Fs for the June quarter, and whose portfolios contained at least 5 long positions in companies valued at $1 billion, revealed some startling...
Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns
The majority of hedge funds and other top money managers tend to have a long-term focus when they make investments.
This Healthcare Fund Just Had A Huge Q3: Here's How
The mainstream media likes taking shots at hedge funds because they are easy targets.
Ariad Pharmaceuticals, Inc. (ARIA)'s Brigatinib Granted Priority Review
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)'s lung cancer drug brigatinib has been accepted for review by the FDA.
Trending Stocks: Diplomat Pharmacy, Facebook, Ariad Pharmaceuticals, and More
Although the broader markets are still down/flat due in large part to Apple Inc.
Tidewater, Inovio, Ariad, and More: What is Going on With These Falling Stocks?
Although the broader markets are in the green today as a wave of M&A activity and a number of solid earnings reports have improved market sentiment, several stocks are not on the receiving end of that...
Here's Why These Five Stocks Are in the Spotlight
While the second trading week of the fourth quarter is officially over, several major stocks are trending over the weekend, including Twitter Inc (NYSE:TWTR), salesforce.com, inc.
Hedge Fund Resource Center Billionaire Hedge Funds
